Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Judge tosses out some claims in Abbott baby formula litigation

Published 05/22/2023, 06:01 PM
Updated 05/23/2023, 12:01 PM
© Reuters. FILE PHOTO: Abbott Laboratories logo is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, U.S., October 18, 2021.  REUTERS/Brendan McDermid
ABT
-

By Jonathan Stempel

(Reuters) - Abbott Laboratories (NYSE:ABT) persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula.

In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bacteria contamination.

The parents said they would not have bought or would have paid less for formula but for the Abbott Park, Illinois-based company's claims that it was safe.

But the judge said the parents lacked standing to sue, saying they did not show which Abbott products or lots were contaminated, or that their children experienced symptoms.

"In short, the plaintiffs received exactly what they say they bargained for: safe infant formula," Kennelly wrote.

The judge also issued decisions that narrowed but did not dismiss two related lawsuits against Abbott.

In one, 28 plaintiffs brought personal injury claims alleging that Abbott's formula caused salmonella contamination, bacterial meningitis and other health problems.

The other lawsuit by eight plaintiffs alleged that Similac products contained heavy metals and were manufactured in unsanitary decisions.

The litigation followed Abbott's February 2022 closure of a baby formula plant in Sturgis, Michigan and subsequent recalls, which together caused a nationwide shortage of formula.

Last May, Food and Drug Administration Commissioner Robert Califf told Congress that conditions in the plant were "egregiously unsanitary." The plant reopened in July.

In a statement, Abbott said it believed the lawsuits were without merit. It also said no "sealed, distributed product" from the Michigan plant had tested positive for salmonella or for Cronobacter sakazakii, a bacteria that can cause meningitis.

Sam Geisler, a lawyer at Aylstock, Witkin, Kreis, & Overholtz co-leading the litigation, said the plaintiffs were reviewing their next steps.

"The end goal has been, is now, and will continue to be holding Abbott accountable for putting the lives of the most vulnerable at risk," Geisler said in an email.

© Reuters. FILE PHOTO: Abbott Laboratories logo is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, U.S., October 18, 2021.  REUTERS/Brendan McDermid

Separate nationwide litigation before a different Chicago judge involves claims that Abbott's formula caused a deadly illness in preterm infants. Abbott has denied those claims.

The cases are: In re Recalled Abbott Infant Formula Products Liability Litigation, U.S. District Court, Northern District of Illinois, No. 22-04148; and Willoughby et al v. Abbott Laboratories in the same court, Nos. 22-01322 and 23-00338.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.